Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01934478

Enrollment

Registered

2013-09-04

Start date

2013-08-31

Completion date

2022-12-30

Last updated

2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Keywords

Breast, Cancer, Human Epidermal Growth Factor 2 (Her2), irradiation

Brief summary

Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* histological confirmed advanced breast cancer * cancer sample can be obtained by fine needle biopsy * IHC and FISH confirmed Her2 negative * radiotherapy indication for local residual cancer

Exclusion criteria

* no radiotherapy indication * patient refuse

Design outcomes

Primary

Measure	Time frame	Description
Her2 changes during radiotherapy	every week up to 6 weeks	biopsy is obtained by fine needle biopsy，Her2 is checked by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH).

Countries

China

Outcome results